vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与DigitalOcean Holdings, Inc.（DOCN）财务数据对比。点击上方公司名可切换其他公司
DigitalOcean Holdings, Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.6倍（$242.4M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 10.6%，领先23.9%），DigitalOcean Holdings, Inc.同比增速更快（18.3% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $31.1M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 14.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
CPRX vs DOCN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $242.4M |
| 净利润 | $52.7M | $25.7M |
| 毛利率 | 82.9% | 58.7% |
| 营业利润率 | 40.5% | 16.0% |
| 净利率 | 34.5% | 10.6% |
| 营收同比 | 7.6% | 18.3% |
| 净利润同比 | -5.8% | 40.5% |
| 每股收益（稀释后） | $0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $242.4M | ||
| Q3 25 | $148.4M | $229.6M | ||
| Q2 25 | $146.6M | $218.7M | ||
| Q1 25 | $141.4M | $210.7M | ||
| Q4 24 | $141.8M | $204.9M | ||
| Q3 24 | $128.7M | $198.5M | ||
| Q2 24 | $122.7M | $192.5M | ||
| Q1 24 | $98.5M | $184.7M |
| Q4 25 | $52.7M | $25.7M | ||
| Q3 25 | $52.8M | $158.4M | ||
| Q2 25 | $52.1M | $37.0M | ||
| Q1 25 | $56.7M | $38.2M | ||
| Q4 24 | $55.9M | $18.3M | ||
| Q3 24 | $43.9M | $32.9M | ||
| Q2 24 | $40.8M | $19.1M | ||
| Q1 24 | $23.3M | $14.1M |
| Q4 25 | 82.9% | 58.7% | ||
| Q3 25 | 84.7% | 59.6% | ||
| Q2 25 | 85.9% | 59.9% | ||
| Q1 25 | 87.3% | 61.4% | ||
| Q4 24 | 84.7% | 57.1% | ||
| Q3 24 | 85.0% | 60.2% | ||
| Q2 24 | 87.4% | 61.0% | ||
| Q1 24 | 87.3% | 60.7% |
| Q4 25 | 40.5% | 16.0% | ||
| Q3 25 | 44.7% | 19.6% | ||
| Q2 25 | 45.2% | 16.3% | ||
| Q1 25 | 44.8% | 17.9% | ||
| Q4 24 | 44.3% | 15.9% | ||
| Q3 24 | 39.6% | 12.4% | ||
| Q2 24 | 44.2% | 11.6% | ||
| Q1 24 | 27.5% | 6.2% |
| Q4 25 | 34.5% | 10.6% | ||
| Q3 25 | 35.6% | 69.0% | ||
| Q2 25 | 35.6% | 16.9% | ||
| Q1 25 | 40.1% | 18.1% | ||
| Q4 24 | 39.4% | 8.9% | ||
| Q3 24 | 34.1% | 16.6% | ||
| Q2 24 | 33.2% | 9.9% | ||
| Q1 24 | 23.6% | 7.7% |
| Q4 25 | $0.40 | $0.23 | ||
| Q3 25 | $0.42 | $1.51 | ||
| Q2 25 | $0.41 | $0.39 | ||
| Q1 25 | $0.45 | $0.39 | ||
| Q4 24 | $0.44 | $0.21 | ||
| Q3 24 | $0.35 | $0.33 | ||
| Q2 24 | $0.33 | $0.20 | ||
| Q1 24 | $0.19 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $254.5M |
| 总债务越低越好 | — | $1.3B |
| 股东权益账面价值 | $954.3M | $-28.7M |
| 总资产 | $1.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $254.5M | ||
| Q3 25 | $689.9M | $236.6M | ||
| Q2 25 | $652.8M | $387.7M | ||
| Q1 25 | $580.7M | $360.4M | ||
| Q4 24 | $517.6M | $428.4M | ||
| Q3 24 | $442.3M | $439.9M | ||
| Q2 24 | $375.7M | $443.1M | ||
| Q1 24 | $310.4M | $419.1M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $954.3M | $-28.7M | ||
| Q3 25 | $920.2M | $-69.6M | ||
| Q2 25 | $856.0M | $-175.2M | ||
| Q1 25 | $794.3M | $-210.7M | ||
| Q4 24 | $727.6M | $-203.0M | ||
| Q3 24 | $660.9M | $-211.7M | ||
| Q2 24 | $608.7M | $-253.8M | ||
| Q1 24 | $561.4M | $-286.1M |
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.7B | ||
| Q1 25 | $908.9M | $1.6B | ||
| Q4 24 | $851.4M | $1.6B | ||
| Q3 24 | $772.0M | $1.5B | ||
| Q2 24 | $706.4M | $1.5B | ||
| Q1 24 | $646.7M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $57.3M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $31.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 12.8% |
| 资本支出强度资本支出/营收 | 0.0% | 10.8% |
| 现金转化率经营现金流/净利润 | 0.85× | 2.23× |
| 过去12个月自由现金流最近4个季度 | — | $180.5M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $57.3M | ||
| Q3 25 | $32.4M | $95.8M | ||
| Q2 25 | $71.3M | $92.4M | ||
| Q1 25 | $60.0M | $64.1M | ||
| Q4 24 | $70.9M | $71.3M | ||
| Q3 24 | $72.9M | $73.4M | ||
| Q2 24 | $64.1M | $71.3M | ||
| Q1 24 | $31.9M | $66.7M |
| Q4 25 | $44.9M | $31.1M | ||
| Q3 25 | — | $88.0M | ||
| Q2 25 | $71.3M | $59.3M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | $70.8M | $26.1M | ||
| Q3 24 | $72.6M | $16.0M | ||
| Q2 24 | $64.1M | $39.5M | ||
| Q1 24 | $31.7M | $23.0M |
| Q4 25 | 29.4% | 12.8% | ||
| Q3 25 | — | 38.3% | ||
| Q2 25 | 48.6% | 27.1% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | 49.9% | 12.7% | ||
| Q3 24 | 56.4% | 8.1% | ||
| Q2 24 | 52.3% | 20.5% | ||
| Q1 24 | 32.2% | 12.5% |
| Q4 25 | 0.0% | 10.8% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 15.2% | ||
| Q1 25 | 0.0% | 29.4% | ||
| Q4 24 | 0.1% | 22.1% | ||
| Q3 24 | 0.2% | 28.9% | ||
| Q2 24 | 0.0% | 16.6% | ||
| Q1 24 | 0.2% | 23.6% |
| Q4 25 | 0.85× | 2.23× | ||
| Q3 25 | 0.61× | 0.60× | ||
| Q2 25 | 1.37× | 2.50× | ||
| Q1 25 | 1.06× | 1.68× | ||
| Q4 24 | 1.27× | 3.91× | ||
| Q3 24 | 1.66× | 2.23× | ||
| Q2 24 | 1.57× | 3.73× | ||
| Q1 24 | 1.37× | 4.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
